Crysalin appoints Brister as chairman
This article was originally published in Scrip
Crysalin, a UK protein structure determination company spun out of the University of Oxford in 2007, has appointed David Brister as chairman. He has more than 20 years' experience in private equity and venture capital, most notably at 3i and MVM. He was an investor in Cambridge Antibody Technology, Acambis and Oxford GlycoSciences and was chairman of Domantis for five years from its inception. He has also held the role of chief business officer at Evotec.